Advancing Precision Intradermal Therapeutics
BETTER DELIVERY. BETTER MEDICINES.
Pipeline
Gylden is advancing therapeutic programs powered by two proprietary intradermal platforms. From our Phase 3 migraine program to next-generation vaccines and immunotherapies, each program is built on the unique biology of the dermis and the potential of precision intradermal delivery.
Preclinical
Phase 1 / 2
Phase 3
Approval
Commercial
Zograine™
Phase 3 Complete
NDA Resubmission
COVID Vaccine
Clinical
Dengue Vaccine
Clinical
Chikungunya Vaccine
Preclinical, Phase 1 Approved
Oncology GNP
Discovery
Ebola Vaccine
Discovery
Interested in partnering with Gylden?
Our proprietary delivery and immune activation platforms are designed to support a broad range of therapeutic applications. We welcome discussions with pharmaceutical, biotechnology, and strategic partners exploring next-generation intradermal therapies.